Document is current
Any future updates will be listed below
-
Authors
Jiang, Wenlu
Pang, Xiaoxiao
Ha, Pin https://orcid.org/0000-0002-8934-0874
Li, Chenshuang
Chang, Grace Xinlian
Zhang, Yuxin
Bossong, Lawrence A.
Ting, Kang https://orcid.org/0009-0003-5419-7152
Soo, Chia https://orcid.org/0000-0003-2444-5963
Zheng, Zhong https://orcid.org/0000-0002-4905-3563
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R44DE024692)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (SB1DE026972)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R44AR064126)
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 2 April 2025
First Online: 12 April 2025
Competing interests
: Drs. Kang Ting, Chia Soo, and Zhong Zheng are inventors of fibromodulin-related patents assigned to UCLA. Drs. Kang Ting, Chia Soo, and Zhong Zheng are founders of Scarless Laboratories Inc. and Saint Therapeutics Inc., which sublicense fibromodulin-related patents from the UC Regents, who also hold equity in the company. Drs. Kang Ting, Chia Soo, and Zhong Zheng are also officers of Scarless Laboratories, Inc. and Saint Therapeutics Inc. The remaining authors declare no competing interests.
